# Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

> **NCT02939989** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 33 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Glecaprevir/Pibrentasvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02939989
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2021-05-07
- **Final completion:** 2021-07-30
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939989, "Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02939989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*